The cagrilintide and semaglutide blend, known as CagriSema, pairs an amylin analog with a GLP-1 drug. Here's what trials show and why it's not FDA-approved.
The cagrilintide and semaglutide blend is an investigational, once-weekly injection that pairs an amylin analog (cagrilintide) with a GLP-1 receptor agonist (semaglutide) in a single fixed dose. Drug developers call the combination CagriSema and are studying it mainly for obesity and type 2 diabetes. It is not FDA-approved for any use in the United States, so outside of a clinical trial it is not a legal prescription product.
What the Cagrilintide and Semaglutide Blend Actually Is
Cagrilintide and semaglutide are two separate molecules that are combined in one injection pen. Semaglutide is the GLP-1 medicine sold as Ozempic, Wegovy, and Rybelsus. Cagrilintide is a long-acting synthetic analog of amylin, a hormone the pancreas releases alongside insulin to help regulate blood sugar and appetite.
The blend exists because the two drugs act on different receptors. Researchers hope that hitting an amylin pathway and a GLP-1 pathway at the same time produces stronger appetite suppression than either drug alone.
Some people search for a "cagrilintide--semaglutide blend" or a "cagrilintide semaglutide blend." Every version of that phrasing points to the same fixed-dose combination product, not to two vials mixed at home.
How the Two Components Work
Semaglutide activates GLP-1 receptors in the brain and digestive tract. It slows gastric emptying, improves satiety signaling, and reduces appetite.
Cagrilintide activates amylin receptors and calcitonin receptors, which also influence how full a person feels and how quickly food moves through the gut.
Because the mechanisms overlap only partially, the theory is that combining cagrilintide and semaglutide can lower appetite through two channels instead of one. That hypothesis is exactly what the Phase 3 REDEFINE trials were built to test.
| Feature | Cagrilintide | Semaglutide | Fixed-dose blend |
|---|---|---|---|
| Drug class | Amylin analog | GLP-1 receptor agonist | Two drugs, one injection |
| Main receptors | Amylin and calcitonin | GLP-1 | Both |
| Dosing frequency | Once weekly | Once weekly (injectable) | Once weekly |
| FDA approval | Not approved | Approved as Ozempic, Wegovy, Rybelsus | Not approved |
| Trial dose in the combination | 2.4 mg | 2.4 mg | 2.4 mg / 2.4 mg |
Cagrilintide Semaglutide Dosage Used in Trials
The most studied dose is 2.4 mg of cagrilintide plus 2.4 mg of semaglutide, injected once weekly. Participants begin at lower doses and step up over several weeks to limit gastrointestinal side effects.
There is no standard cagrilintide semaglutide dosage available outside a research protocol. Doses in trials are fixed by the study design, and a clinician cannot currently prescribe the combination at all.
- Early weeks: low starting doses used to check tolerability
- Middle weeks: scheduled step-ups toward the target dose
- Maintenance: 2.4 mg of cagrilintide plus 2.4 mg of semaglutide once weekly in the highest-dose arm
Anything marketed as "cagrilintide and semaglutide 2.4 mg" from an online vendor is not the same product as the investigational pharmaceutical. Research-grade powders are not made to pharmacy standards and have not been tested in humans.
What the Clinical Trials Have Reported
The REDEFINE program enrolled thousands of adults with obesity, with or without type 2 diabetes. In the REDEFINE 1 trial, the 2.4 mg/2.4 mg dose produced average weight reductions of roughly 20% or more over about 68 weeks, depending on how the data were analyzed.
That result was strong but fell short of the 25% average reduction the sponsor had publicly targeted. Gastrointestinal side effects were the most common reason participants stopped treatment.
Nausea, vomiting, diarrhea, and constipation appeared in a meaningful share of participants, which is typical for this drug class.
Approval Status and Legal Realities
Semaglutide is FDA-approved for type 2 diabetes, chronic weight management, and cardiovascular risk reduction under several brand names. Cagrilintide is not approved in any form, and the combination product is not approved either.
No pharmacy can legally dispense a cagrilintide and semaglutide blend today. The FDA has also warned about compounded GLP-1 products that were never reviewed for safety, purity, or effectiveness.
How This Compares With Other Research Options
Anyone weighing the blend against other molecules should look at both mechanism and evidence. Retatrutide, for example, targets three receptors instead of two.
The main difference between retatrutide and semaglutide comes down to receptor coverage and trial stage: retatrutide is a single triple-agonist molecule, while semaglutide is a single GLP-1 molecule.
Blends are also common in peptide research that has nothing to do with appetite. People looking into bpc-157 and tb-500 blend dosage, for instance, are working with a different category of compounds studied for tissue repair.
Mixing categories, or assuming any two injectables can be combined safely, is a common and potentially dangerous mistake.
Safety Considerations
GLP-1 and amylin drugs share a similar side effect profile: nausea, vomiting, diarrhea, constipation, and injection site reactions. Uncommon but serious risks include pancreatitis, gallbladder disease, and gastroparesis.
Rodent studies of GLP-1 drugs showed thyroid C-cell tumors, and this drug class is not recommended during pregnancy.
Anyone considering a GLP-1 or amylin-based therapy should speak with a licensed healthcare professional rather than sourcing research chemicals online. Dosing errors with unregulated products can cause severe illness.
Key Takeaways
- The cagrilintide and semaglutide blend is an investigational fixed-dose combination known as CagriSema.
- The blend is not FDA-approved, and no pharmacy can legally dispense it.
- Amylin and GLP-1 pathways are different, which is the scientific rationale for combining the two drugs.
- Trials tested a 2.4 mg/2.4 mg weekly dose and reported substantial, but not risk-free, weight loss.
- Evidence for the blend comes from controlled trials; evidence for vendor-sold versions does not exist.
Frequently Asked Questions
Is the cagrilintide and semaglutide blend FDA-approved?
No. The combination, often called CagriSema, is still investigational and has not been approved by the FDA for any indication. Semaglutide alone is approved under brand names such as Ozempic, Wegovy, and Rybelsus, but cagrilintide is not approved in any form. That means the blend can only be obtained through a clinical trial.
What dose of cagrilintide and semaglutide is used in trials?
The most-studied dose is 2.4 mg of cagrilintide combined with 2.4 mg of semaglutide, given as one weekly injection. Participants start lower and step up gradually to reduce gastrointestinal side effects. There is no standard dose available outside a research protocol.
How much weight loss did the cagrilintide and semaglutide blend produce?
In the REDEFINE 1 trial, the 2.4 mg/2.4 mg dose produced average weight reductions of roughly 20% or more over about 68 weeks, depending on how the data were analyzed. That was below the 25% average the sponsor had targeted. Gastrointestinal side effects were the leading reason people stopped treatment.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.